A4V

iXCells Biotechnologies Expands CRISPR-Cas9 Cell Products and Genome Engineering Services

Retrieved on: 
Tuesday, May 16, 2023
Research, Pharmaceutical, Oncology, Mental Health, Medical Devices, Genetics, Health Technology, Clinical Trials, Science, Neurology, Biotechnology, Stem Cells, Health, CRISPR, IPSC, Frameshift mutation, Gene editing, BFNE, Mutation, Epistasis, Parkinson, LCL, DSM-IV codes, Neuron, SOD1, Fragile X syndrome, TDP43, DMD, Corporation, Drug discovery, Commercial Operating System, ALS, A4V, Vaccine, Fibroblast

iXCells Biotechnologies (“iXCells” or the “Company”), a provider of cell products and drug discovery services to the worldwide academic, biotech and pharmaceutical communities, today announced expansion of its CRISPR-Cas9 product and custom services offering, with special focus on induced pluripotent stem cell (“iPSC”) derived cell models.

Key Points: 
  • iXCells Biotechnologies (“iXCells” or the “Company”), a provider of cell products and drug discovery services to the worldwide academic, biotech and pharmaceutical communities, today announced expansion of its CRISPR-Cas9 product and custom services offering, with special focus on induced pluripotent stem cell (“iPSC”) derived cell models.
  • The company is also developing new iPSC derived disease models, such as Alzheimer’s, BFNE, DMD, Parkinson and Fragile X syndrome.
  • Dr Nianwei Lin, the company’s President and Co-Founder, commented, “iXCells can generate iPSC disease relevant cell models by reprogramming somatic cells like PBMCs, Fibroblasts, LCL, etc.
  • Standard products are listed on our website with more products in our R&D pipeline, and our scientific team can quickly develop custom disease models for each client through our CRO services offering.”
    “iXCells offers engineered cell products and related services for drug discovery and development using CRISPR-Cas9 technology under a global license agreement.

Motor neurons derived from patients point to new possible drug target for ALS

Retrieved on: 
Tuesday, June 8, 2021
Branches of biology, Biology, Neurological disorders, Induced stem cells, Motor neuron diseases, Stem cells, Metalloproteins, Oxidoreductases, SOD1, A4V, Induced pluripotent stem cell, Amyotrophic lateral sclerosis

Researchers at Boston Children's Hospital, working in collaboration with Pfizer, now report a high-throughput target and drug discovery platform using motor neurons made from ALS patients.

Key Points: 
  • Researchers at Boston Children's Hospital, working in collaboration with Pfizer, now report a high-throughput target and drug discovery platform using motor neurons made from ALS patients.
  • To create the motor neurons used for drug screening, the team used induced pluripotent stem cells, made by the lab of Kevin Eggan at Harvard University from tissue samples of patients with ALS who carried the SOD1(A4V) mutation.
  • Woolf and colleagues previously showed that human motor neurons with ALS mutations are more excitable than normal motor neurons.
  • After three rounds of screening, they found 67 compounds that reduced the hyperexcitability of the patient-derived motor neurons, without causing toxicity.